Essex Woodlands Management, Inc. has disclosed its latest holdings in a recent 13F-HR filing, revealing a total of $323 million in Section 13(f) securities held by its affiliated investment funds as of September 30, 2026. This filing is significant as it showcases the company’s ongoing investment strategy within the healthcare sector, particularly in biotechnology.

The filing, submitted on November 6, 2026, indicates that Essex Woodlands continues to maintain a strong presence in the investment landscape, particularly in sectors that show potential for growth. The report highlights the firm’s strategy of investing in companies that are innovating within the healthcare industry.

Background

Essex Woodlands Management, Inc. is a private investment firm based in The Woodlands, Texas. The company is classified under the SIC code for investment advice and management. It has been actively filing with the SEC, with its most recent filings including several 13F-HR forms over the past year. The firm’s focus is primarily on healthcare investments, which positions it well in a sector that continues to evolve rapidly.

What the Filing Says

The 13F-HR filing states, "Consistent with past practice, Essex Woodlands Management, Inc. is filing this Form 13F-HR as the reporting manager with respect to Section 13(f) securities held by affiliated investment funds of EWM as of September 30, 2026." This indicates a consistent approach in reporting their investments, which is crucial for transparency in the investment community.

Impact

This filing may affect various stakeholders, including investors, analysts, and competitors in the biotechnology and healthcare sectors. By revealing its significant holdings in companies like BioVentus Inc. and EyenPoint Pharmaceuticals Inc., Essex Woodlands Management provides insights into its investment strategies and market outlook.

What's Next

The filing does not say what happens next. However, it is expected that Essex Woodlands will continue to monitor its investments and may provide updates in future filings.